{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:23:10Z","timestamp":1791595390546,"version":"4.3.4"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,2,16]],"date-time":"2015-02-16T00:00:00Z","timestamp":1424044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Dermatology"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oclacitinib is safe and effective for treating dogs with pruritus associated with allergic and atopic dermatitis, based on randomized clinical trials of up to 4\u00a0months duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>This study assessed long\u2010term safety, efficacy and quality of life of oclacitinib\u2010treated dogs enrolled in a compassionate use programme.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Two hundred and forty\u2010seven client\u2010owned dogs with allergic skin disease that had previously benefited from oclacitinib therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Dogs were enrolled in an open\u2010label study at 26 veterinary clinics. Dogs received 0.4\u20130.6\u00a0mg\/kg oclacitinib twice a day for 14\u00a0days, then once a day for up to 630\u00a0days. Assessments were performed at ~90\u00a0day intervals. Owners completed a quality\u2010of\u2010life survey and assessed pruritus using a Visual Analog Scale (\n                      <jats:styled-content style=\"fixed-case\">VAS<\/jats:styled-content>\n                      ) at each clinic visit. Veterinarians assessed dermatitis using a similar\n                      <jats:styled-content style=\"fixed-case\">VAS<\/jats:styled-content>\n                      . Abnormal health events, concomitant medication and clinical pathology results were summarized.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Visual Analog Scale scores showed improvement from baseline at all time points. The percentage of dogs showing \u226550% reduction from baseline on day\u00a090 was 63.9% for pruritus and 66.4% for dermatitis. Owners saw a positive impact on quality of life in &gt;91% of all dogs. Urinary tract infection\/cystitis, vomiting, otitis, pyoderma and diarrhoea were the most frequently reported (&gt;5% of dogs) abnormal clinical signs. Haematology and serum chemistry means remained within the normal reference ranges. Concomitant medications were well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and clinical importance<\/jats:title>\n                    <jats:p>Results indicated that oclacitinib was safe and efficacious for long\u2010term use and improved the quality of life for dogs in this study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/vde.12194","type":"journal-article","created":{"date-parts":[[2015,2,16]],"date-time":"2015-02-16T04:52:46Z","timestamp":1424062366000},"page":"171","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Long\u2010term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life"],"prefix":"10.1111","volume":"26","author":[{"given":"Sallie B.","family":"Cosgrove","sequence":"first","affiliation":[{"name":"Zoetis Inc., Veterinary Medicine Research and Development 333 Portage Street Kalamazoo MI 49007 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn M.","family":"Cleaver","sequence":"additional","affiliation":[{"name":"Zoetis Inc., Veterinary Medicine Research and Development 333 Portage Street Kalamazoo MI 49007 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie L.","family":"King","sequence":"additional","affiliation":[{"name":"Zoetis Inc., Veterinary Medicine Research and Development 333 Portage Street Kalamazoo MI 49007 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy R.","family":"Gilmer","sequence":"additional","affiliation":[{"name":"Zoetis Inc., Veterinary Medicine Research and Development 333 Portage Street Kalamazoo MI 49007 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"Daniels","sequence":"additional","affiliation":[{"name":"Zoetis Inc., Veterinary Medicine Research and Development 333 Portage Street Kalamazoo MI 49007 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody A.","family":"Wren","sequence":"additional","affiliation":[{"name":"Zoetis Inc., Veterinary Medicine Research and Development 333 Portage Street Kalamazoo MI 49007 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Stegemann","sequence":"additional","affiliation":[{"name":"Zoetis Inc., Veterinary Medicine Research and Development Mercuriusstraat 20 Zaventem B\u20101930 Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,2,16]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"Zoetis Online website.Apoquel\u00aeproduct label. Available at:https:\/\/www.zoetisus.com\/bmst-minisite-apoquel\/documents\/finalapoquel_pi_8_5x11.pdf?utm_source=Prescribing&utm_medium=click&utm_campaign=Apoquelztssite. Accessed Jan 6 2015."},{"key":"e_1_2_6_3_1","unstructured":"US Food and Drug Administration website.Apoquel FOI. Available at:http:\/\/www.fda.gov\/downloads\/AnimalVeterinary\/Products\/ApprovedAnimalDrugProducts\/FOIADrugSummaries\/UCM363901.pdf. Accessed Dec 09 2014."},{"key":"e_1_2_6_4_1","unstructured":"Veterinary Drugs Directorate of Health Canada website.Apoquel. Available at:http:\/\/webprod5.hc-sc.gc.ca\/noc-ac\/index-eng.jsp. Accessed Jan 6 2015.[Note: Under Brand\/Product Name type Apoquel and you will have a list of all strengths approved and the date of NOC.]"},{"key":"e_1_2_6_5_1","unstructured":"European Medicines Agency website.Apoquel. Available at:http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/veterinary\/medicines\/002688\/vet_med_000280.jsp&mid=WC0b01ac058001fa1. Accessed Oct 9 2013."},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12047"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12088"},{"key":"e_1_2_6_8_1","first-page":"381","article-title":"Selection of an efficacious dosing regimen of oclacitinib (Apoquel\u00ae) for the control of atopic dermatitis in client\u2010owned dogs using visual analog scale and CADESI Scores","volume":"24","author":"Cosgrove SB","year":"2013","journal-title":"Vet Dermatol"},{"key":"e_1_2_6_9_1","first-page":"38","article-title":"A multicentre clinical trial to evaluate efficacy and field safety of oclacitinib","volume":"23","author":"Cosgrove SB","year":"2012","journal-title":"Vet Dermatol"},{"key":"e_1_2_6_10_1","unstructured":"US Food and Drug Administration website.Access to investigational drugs outside of a clinical trial (expanded access). Available at:http:\/\/www.fda.gov\/forpatients\/other\/expandedaccess\/default.htm. Accessed Jan 6 2015."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2009.00784.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3164.2003.00335.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00754.x"},{"key":"e_1_2_6_14_1","unstructured":"Good Clinical Practice website.International co\u2010operation on harmonisation of technical requirements for registration of veterinary medicinal products (VICH). Available at:http:\/\/www.fda.gov\/downloads\/AnimalVeterinary\/GuidanceComplianceEnforcement\/GuidanceforIndustry\/UCM052417.pdf. Accessed Jan 6 2015."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2010.00954.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2011.00956.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2009.00781.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2010.00899.x"},{"key":"e_1_2_6_19_1","unstructured":"International co\u2010operation on harmonisation of technical requirements for registration of veterinary medicinal products (VICH). Pharmacovigilance of veterinary medicinal products webpage: \u201cManagement of adverse event reports (AERs). Available at pharmacovigilance of veterinary medicinal products: management of adverse event reports (AERs) website. Available at:\u00a0http:\/\/www.fda.gov\/downloads\/AnimalVeterinary\/GuidanceComplianceEnforcement\/GuidanceforIndustry\/UCM052657.pdf. Accessed Jan 6 2015."},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2008.00728.x"},{"key":"e_1_2_6_21_1","first-page":"1748","volume-title":"Ettinger and Feldman's Textbook of Veterinary Internal Medicine","author":"Lulich JP","year":"2000"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2008.0190.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0442.1989.tb00787.x"},{"key":"e_1_2_6_24_1","first-page":"103","volume-title":"Skin Tumors of the Dog and Cat","author":"Goldschmidt MH","year":"1992"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-072160558-6.50007-1"},{"key":"e_1_2_6_26_1","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.2460\/ajvr.1982.43.11.2057","article-title":"Variation in age at death of dogs of different sexes and breeds","volume":"43","author":"Bronson RT","year":"1982","journal-title":"Am J Vet Res"}],"container-title":["Veterinary Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fvde.12194","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vde.12194","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vde.12194","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vde.12194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T22:47:48Z","timestamp":1747608468000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vde.12194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,16]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/vde.12194"],"URL":"https:\/\/doi.org\/10.1111\/vde.12194","archive":["Portico"],"relation":{},"ISSN":["0959-4493","1365-3164"],"issn-type":[{"value":"0959-4493","type":"print"},{"value":"1365-3164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,16]]},"assertion":[{"value":"2014-11-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-02-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}